{
  "docId": "019de073-7087-77cd-a846-97dda09bac98",
  "docSlug": "031593eaf739f40f0f0c49214c912ed3",
  "documentTitle": "9 Meters Biopharma | Investor Presentation Deck | 30 slides",
  "authorId": "9-meters-biopharma",
  "authorName": "9 Meters Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 30,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide highlights the efficacy of the 50 mg Q2W dose compared to other cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7087-77cd-a846-97dda09bac98/22",
  "deckHref": "/decks/019de073-7087-77cd-a846-97dda09bac98",
  "deckJsonHref": "/decks/019de073-7087-77cd-a846-97dda09bac98.json",
  "deckAnchorHref": "/decks/019de073-7087-77cd-a846-97dda09bac98#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.56,
        "x": 0.22,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Bar chart showing 89%, 67%, and 33% reduction rates for 50mg Q2W, 50mg weekly, and 100mg Q2W respectively.",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85e0de76-f905-438f-97ec-d5fc2c60a368",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.25,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Of 9 patients on vurolenatide (all doses), 34 of 54 weekly observations (63%) had a TSO decrease.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16781a87-77af-4f38-a020-3bf018cf4056",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.18,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Observation weeks per dose group = 18 (3 patients x 6 weeks) * TSO reduction based on change from baseline by week",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45187b47-577c-4ec3-abed-8d215bca6f12",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.84,
        "x": 0.08,
        "y": 0.12
      },
      "kind": "title",
      "text": "50 mg Q2W arm shows 16 of 18 weeks with consistent TSO reduction*",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "066de8d3-da12-46c8-b480-07fae4affe32",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 19,
      "beatId": "01706216-583a-4df3-91f5-747d626ebb59",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 19-23 show traction and results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}